Vascular complications of diabetes mellitus: what role for phospholipid-binding antibodies?
Authors:
Open Access
- 1 September 1998
- journal article
- research article
- Published by SAGE Publications in Lupus
- Vol. 7 (7) , 469-474
Abstract
Vascular complications are the main cause of morbidity in diabetes mellitus. However, the risk factors for vascular disease remain uncompletely elucidated. It has been previously suggested that factors other than glycemia may contribute to the development of vasculopathy. In this study we determined the prevalence of phospholipid-binding antibodies in uncomplicated and complicated diabetes. We studied 53 uncomplicated diabetic patients, with type 1 (n=32) or type 2 (n=21) diabetes; 23 diabetic patients with proliferative retinopathy; 28 diabetic patients with an overt nephropathy; 37 diabetic patients with macroangiopathy and 22 non diabetic control patients. Both lupus anticoagulant and anticardiolipin antibodies were determined.Other risk factors for macroangiopathy were analysed. The prevalence of phospholipid-binding antibodies was similar in uncomplicated diabetic patients and in controls (type 1 diabetes: 9.4%; type 2 diabetes: 9.5%; control group: 4.6%; P=0.76). In complicated diabetes, the frequency of these antibodies was increased only in patients with overt nephropathy (32.1%, P=0.01) or with macroangiopathy (32.4%, P=0.01) while patients with isolated retinopathy were comparable with uncomplicated diabetic patients (4.3%, P=0.66).Uncomplicated diabetes was not associated with phospholipid-binding antibodies. We found a higher prevalence of these antibodies in diabetic patients with macroangiopathy or nephropathy. These results suggest a potential role of phospholipid-binding antibodies in the progression of vascular complications in diabetes mellitus.Keywords
This publication has 36 references indexed in Scilit:
- Anticardiolipin antibodies in children and adolescents with insulin-dependent diabetes mellitusEuropean Journal of Pediatrics, 1995
- Antiphospholipid Antibodies in Coronary Artery Disease: A ReviewSeminars in Thrombosis and Hemostasis, 1994
- Production of anti-cardiolipin antibody in AKR/J mice with streptozocin-induced insulitis and diabetesDiabetes Research and Clinical Practice, 1993
- Antiphospholipid antibodies and recurrent pregnancy loss: Correlation between the activated partial thromboplastin time and antibodies against phosphatidylserine and cardiolipinAmerican Journal of Obstetrics and Gynecology, 1990
- Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H).Proceedings of the National Academy of Sciences, 1990
- Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactorThe Lancet, 1990
- Antiphospholipid Antibodies: Anticardiolipin and the Lupus Anticoagulant in Systemic Lupus Erythematosus (SLE) and in Non-SLE DisordersAnnals of Internal Medicine, 1990
- ANTIPHOSPHOLIPID ANTIBODIESBritish Journal of Haematology, 1990
- Scientific and Standardization Committee Communications Comparison of Test Methods for the Lupus Anticoagulant: International Survey on Lupus Anticoagulants-I (ISLA-1)Thrombosis and Haemostasis, 1990
- Anticardiolipin antibody levels in diabetic subjects with and without coronary artery diseasePostgraduate Medical Journal, 1989